Skip to content

Search

COVID-19 risks explained for babies, children and pregnant women

Many parents may be feeling anxious and confused about what COVID-19 means for pregnant women, babies and children.

It’s not just physical illness that will have an impact: A ground-breaking study is investigating the effect of COVID-19 on community wellbeing

In an Australian-first study, researchers at The Kids Research Institute Australia are investigating the effects of COVID-19 on the wellbeing of more than 2,000 families in the northern suburbs of Perth, measuring their perceived stress, financial hardship and family functioning during the pandemic.

Community advocate jumps on board with new COVID-19 advisory group

Like many of us, consumer and community advocate Catherine Hughes is worried about the impact of COVID-19. So she joined Australia’s first COVID-19 consumer reference group to be a voice for the community.

Rapidly assembled advisory group to offer community take on COVID-19 research

The speed with which research projects on the coronavirus have been put together has consumer advocates concerned that a vital voice will be missing – that of the community.

Australia one step closer to COVID-19 shot for under 5s

Australia’s TGA has granted a provisional determination to Pfizer, allowing the pharmaceutical company to apply for approval to extend its COVID-19 vaccine to children aged 6 mths - 4 yrs.

Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review

The search for clinically effective antivirals against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is ongoing. Repurposing of drugs licensed for non–coronavirus disease 2019 (COVID-19) indications has been extensively investigated in laboratory models and in clinical studies with mixed results.

Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial

We previously reported the efficacy of the adjuvanted-protein COVID-19 vaccine candidate S-Trimer (SCB-2019) in adults who showed no evidence of previous exposure to SARS-CoV-2. In this study, we aimed to investigate the extent of protection afforded by previous exposure to SARS-CoV-2 on subsequent COVID-19 infection, as well as the efficacy, safety, and reactogenicity of SCB-2019 in participants who were enrolled in the Study.

The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021

Peter Britta Richmond Regli-von Ungern-Sternberg AM FAHMS MBBS MRCP(UK) FRACP MD, PhD, DEAA, FANZA Head, Vaccine Trials Group Chair of Paediatric

The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021

To assess the short term safety of the COVID-19 vaccines Comirnaty (Pfizer–BioNTech BNT162b2) and Vaxzevria (AstraZeneca ChAdOx1) in Australia.

Mind the distance: experiences of non-face-to-face child and youth mental health services during COVID-19 social distancing restrictions in Western Australia

Following the outbreak of COVID-19, social distancing restrictions limited access to face-to-face mental health services in Western Australia (WA), necessitating a rapid transition to non-face-to-face alternatives, including telehealth. The current study investigated barriers and facilitators to telehealth access and engagement, and preferences for child and youth mental health service delivery during and beyond COVID-19.